Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares - Seite 2

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Horizon Therapeutics plc

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the completion, timing, net proceeds of the public offering and the Company’s expected use of the net proceeds. These forward-looking statements are based on Horizon Therapeutics’ current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the satisfaction of customary closing conditions related to the public offering, the fact that Horizon Therapeutics will have discretion in the application of the net proceeds and could use the net proceeds for purposes other than those described in the forward-looking statements and risks associated with the COVID-19 global pandemic. Additional risks and uncertainties relating to the public offering, Horizon Therapeutics and its business can be found under the caption “Risk Factors” in the prospectus supplement relating to the offering and elsewhere in Horizon’s SEC filings and reports, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020. Forward-looking statements speak only as of the date of this press release, and Horizon Therapeutics undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200806006157/en/